HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
View/ Open
Author
Perera, Samanthi A.
Li, Danan
Shimamura, Takeshi
Raso, Maria G.
Ji, Hongbin
Chen, Liang
Borgman, Christa L.
Zaghlul, Sara
Brandstetter, Kathleyn A.
Kubo, Shigeto
Takahashi, Masaya
Chirieac, Lucian R.
Padera, Robert F.
Bronson, Roderick T.
Shapiro, Geoffrey I.
Greulich, Heidi
Meyerson, Matthew
Guertler, Ulrich
Chesa, Pilar Garin
Solca, Flavio
Wistuba, Ignacio I.
Wong, Kwok-Kin
Published Version
https://doi.org/10.1073/pnas.0808930106Metadata
Show full item recordCitation
Perera, S. A., D. Li, T. Shimamura, M. G. Raso, H. Ji, L. Chen, C. L. Borgman, et al. 2009. “HER2YVMA Drives Rapid Development of Adenosquamous Lung Tumors in Mice That Are Sensitive to BIBW2992 and Rapamycin Combination Therapy.” Proceedings of the National Academy of Sciences 106 (2): 474–79. doi:10.1073/pnas.0808930106.Abstract
Mutations in the HER2 kinase domain have been identified in human clinical lung cancer specimens. Here we demonstrate that inducible expression of the most common HER2 mutant (HER2(YVMA)) in mouse lung epithelium causes invasive adenosquamous carcinomas restricted to proximal and distal bronchioles. Continuous expression of HER2YVMA is essential for tumor maintenance, suggesting a key role for HER2 in lung adenosquamous tumorigenesis. Preclinical studies assessing the in vivo effect of erlotinib, trastuzumab, BIBW2992, and/or rapamycin on HER2(YVMA) transgenic mice or H1781 xenografts with documented tumor burden revealed that the combination of BIBW2992 and rapamycin is the most effective treatment paradigm causing significant tumor shrinkage. Immunohistochemical analysis of lung tumors treated with BIBW2992 and rapamycin combination revealed decreased phosphorylation levels for proteins in both upstream and downstream arms of MAPK and Akt/mTOR signaling axes, indicating inhibition of these pathways. Based on these findings, clinical testing of the BIBW2992/rapamycin combination in non-small cell lung cancer patients with tumors expressing HER2 mutations is warranted.Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41542790
Collections
- HMS Scholarly Articles [17714]
Contact administrator regarding this item (to report mistakes or request changes)